semaglutide cardiovascular outcomes 2025 news A Lancet analysis of the SELECT trial concluded that reduced major adverse events by 20% in adults with overweight or obesity, regardless of how much weight patients actually lost semaglutide cardiovascular outcomes news 2025

For example, GLP-1RAs were proven in the clinic to slow the disease progression of Alzheimers disease and Parkinsons disease, attributed in part to their anti-inflammatory and neuroprotective properties [16, 18,19,20,21,22]

Tirzepatide (Mounjaro/Zepbound) may cause slightly more GI side effects overall because it targets two receptors (GLP-1 + GIP), but individual responses vary

Research examines peptide degradation, formulation stability, excipient compatibility, release kinetics, mucosal transport, and structural characteristics that may influence bioavailability

The lactation study used injectable semaglutide and found undetectable milk levels

Patient safety must always take precedence over convenience

Licochalcone a suppresses the proliferation of osteosarcoma cells through autophagy and ATM-Chk2 activation